TW200530235A - Bicycloheteroarylamine compounds as ion channel ligands and uses thereof - Google Patents

Info

Publication number

TW200530235A

TW200530235A TW093139996A TW93139996A TW200530235A TW 200530235 A TW200530235 A TW 200530235A TW 093139996 A TW093139996 A TW 093139996A TW 93139996 A TW93139996 A TW 93139996A TW 200530235 A TW200530235 A TW 200530235A

Authority

TW

Taiwan

Prior art keywords

substituted

unsubstituted

group

amine

aryl

Prior art date

2003-12-24

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 title claims abstract description 296
• 102000004310 Ion Channels Human genes 0.000 title claims description 31
• 239000003446 ligand Substances 0.000 title description 7
• 208000002193 Pain Diseases 0.000 claims abstract description 51
• 230000036407 pain Effects 0.000 claims abstract description 39
• 241000124008 Mammalia Species 0.000 claims abstract description 18
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
• 206010061218 Inflammation Diseases 0.000 claims abstract description 14
• 230000004054 inflammatory process Effects 0.000 claims abstract description 14
• 230000002265 prevention Effects 0.000 claims abstract description 9
• 208000014674 injury Diseases 0.000 claims abstract description 5
• -1 Amine compound Chemical class 0.000 claims description 336
• 125000003118 aryl group Chemical group 0.000 claims description 165
• 239000000203 mixture Substances 0.000 claims description 138
• 239000001257 hydrogen Substances 0.000 claims description 100
• 229910052739 hydrogen Inorganic materials 0.000 claims description 100
• 125000000217 alkyl group Chemical group 0.000 claims description 93
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 93
• 201000010099 disease Diseases 0.000 claims description 89
• 150000001412 amines Chemical class 0.000 claims description 87
• 125000001072 heteroaryl group Chemical group 0.000 claims description 85
• 238000000034 method Methods 0.000 claims description 70
• 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 69
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 68
• 208000024891 symptom Diseases 0.000 claims description 62
• 150000002431 hydrogen Chemical class 0.000 claims description 59
• 125000004404 heteroalkyl group Chemical group 0.000 claims description 54
• OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 claims description 48
• YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 claims description 44
• 125000003545 alkoxy group Chemical group 0.000 claims description 41
• 125000003710 aryl alkyl group Chemical group 0.000 claims description 40
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 37
• 238000006243 chemical reaction Methods 0.000 claims description 37
• 238000006467 substitution reaction Methods 0.000 claims description 34
• 239000002253 acid Substances 0.000 claims description 32
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 31
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 29
• 125000003107 substituted aryl group Chemical group 0.000 claims description 28
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 27
• 150000003839 salts Chemical class 0.000 claims description 27
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 25
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 25
• 125000000304 alkynyl group Chemical group 0.000 claims description 22
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 22
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 22
• 208000004296 neuralgia Diseases 0.000 claims description 22
• 229960002504 capsaicin Drugs 0.000 claims description 21
• 235000017663 capsaicin Nutrition 0.000 claims description 21
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 20
• 150000001540 azides Chemical class 0.000 claims description 19
• 125000000392 cycloalkenyl group Chemical group 0.000 claims description 19
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 19
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 19
• 229940002612 prodrug Drugs 0.000 claims description 19
• 239000000651 prodrug Substances 0.000 claims description 19
• 150000003573 thiols Chemical class 0.000 claims description 19
• 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 19
• 125000002619 bicyclic group Chemical group 0.000 claims description 18
• 125000004663 dialkyl amino group Chemical group 0.000 claims description 18
• NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 claims description 18
• 239000012453 solvate Substances 0.000 claims description 18
• 125000004149 thio group Chemical group *S* 0.000 claims description 18
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 17
• 125000004104 aryloxy group Chemical group 0.000 claims description 16
• 125000000623 heterocyclic group Chemical group 0.000 claims description 16
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 16
• 125000004076 pyridyl group Chemical group 0.000 claims description 16
• FZZMTSNZRBFGGU-UHFFFAOYSA-N 2-chloro-7-fluoroquinazolin-4-amine Chemical class FC1=CC=C2C(N)=NC(Cl)=NC2=C1 FZZMTSNZRBFGGU-UHFFFAOYSA-N 0.000 claims description 15
• 125000001931 aliphatic group Chemical group 0.000 claims description 15
• 229910052736 halogen Inorganic materials 0.000 claims description 15
• 125000000547 substituted alkyl group Chemical group 0.000 claims description 15
• 230000001154 acute effect Effects 0.000 claims description 14
• 125000003368 amide group Chemical group 0.000 claims description 14
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 14
• 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 14
• 150000003254 radicals Chemical class 0.000 claims description 14
• 201000004384 Alopecia Diseases 0.000 claims description 13
• 239000007789 gas Substances 0.000 claims description 13
• 150000002367 halogens Chemical class 0.000 claims description 13
• 125000005553 heteroaryloxy group Chemical group 0.000 claims description 13
• OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 13
• 238000001727 in vivo Methods 0.000 claims description 13
• 229910052757 nitrogen Inorganic materials 0.000 claims description 13
• 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 12
• 229910052796 boron Inorganic materials 0.000 claims description 12
• 150000007857 hydrazones Chemical class 0.000 claims description 12
• 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 12
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 12
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 11
• 208000023275 Autoimmune disease Diseases 0.000 claims description 11
• 125000003277 amino group Chemical group 0.000 claims description 11
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 11
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 11
• 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 11
• 208000010125 myocardial infarction Diseases 0.000 claims description 11
• IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 11
• 241000208140 Acer Species 0.000 claims description 10
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
• 206010046851 Uveitis Diseases 0.000 claims description 10
• 125000003282 alkyl amino group Chemical group 0.000 claims description 10
• 125000001309 chloro group Chemical group Cl* 0.000 claims description 10
• 208000024963 hair loss Diseases 0.000 claims description 10
• 230000003676 hair loss Effects 0.000 claims description 10
• 125000005842 heteroatom Chemical group 0.000 claims description 10
• 210000005036 nerve Anatomy 0.000 claims description 10
• 230000001105 regulatory effect Effects 0.000 claims description 10
• 229910052727 yttrium Inorganic materials 0.000 claims description 10
• 206010019233 Headaches Diseases 0.000 claims description 9
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 9
• 206010028980 Neoplasm Diseases 0.000 claims description 9
• 208000028389 Nerve injury Diseases 0.000 claims description 9
• 208000006011 Stroke Diseases 0.000 claims description 9
• 125000001769 aryl amino group Chemical group 0.000 claims description 9
• 239000000460 chlorine Substances 0.000 claims description 9
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
• 231100000869 headache Toxicity 0.000 claims description 9
• 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 9
• 230000008764 nerve damage Effects 0.000 claims description 9
• 208000021722 neuropathic pain Diseases 0.000 claims description 9
• MFGKTDNWDCJOLN-UHFFFAOYSA-N pyrido[3,4-d]pyrimidin-4-amine Chemical compound N1=CC=C2C(N)=NC=NC2=C1 MFGKTDNWDCJOLN-UHFFFAOYSA-N 0.000 claims description 9
• PWRBCZZQRRPXAB-UHFFFAOYSA-N 3-chloropyridine Chemical compound ClC1=CC=CN=C1 PWRBCZZQRRPXAB-UHFFFAOYSA-N 0.000 claims description 8
• 208000008589 Obesity Diseases 0.000 claims description 8
• 208000018737 Parkinson disease Diseases 0.000 claims description 8
• 208000030886 Traumatic Brain injury Diseases 0.000 claims description 8
• 206010003246 arthritis Diseases 0.000 claims description 8
• 201000011510 cancer Diseases 0.000 claims description 8
• 125000005843 halogen group Chemical group 0.000 claims description 8
• 208000015122 neurodegenerative disease Diseases 0.000 claims description 8
• 235000020824 obesity Nutrition 0.000 claims description 8
• 229910052760 oxygen Inorganic materials 0.000 claims description 8
• 208000023504 respiratory system disease Diseases 0.000 claims description 8
• 239000002689 soil Substances 0.000 claims description 8
• 210000001032 spinal nerve Anatomy 0.000 claims description 8
• 208000004371 toothache Diseases 0.000 claims description 8
• 230000009529 traumatic brain injury Effects 0.000 claims description 8
• 206010065390 Inflammatory pain Diseases 0.000 claims description 7
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 7
• 229910052799 carbon Inorganic materials 0.000 claims description 7
• 206010015037 epilepsy Diseases 0.000 claims description 7
• 230000002757 inflammatory effect Effects 0.000 claims description 7
• 208000017169 kidney disease Diseases 0.000 claims description 7
• 230000004770 neurodegeneration Effects 0.000 claims description 7
• 239000001301 oxygen Substances 0.000 claims description 7
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 7
• 201000000980 schizophrenia Diseases 0.000 claims description 7
• 208000019116 sleep disease Diseases 0.000 claims description 7
• 229910052717 sulfur Inorganic materials 0.000 claims description 7
• 239000000052 vinegar Substances 0.000 claims description 7
• 235000021419 vinegar Nutrition 0.000 claims description 7
• 208000019901 Anxiety disease Diseases 0.000 claims description 6
• 206010003210 Arteriosclerosis Diseases 0.000 claims description 6
• 208000006561 Cluster Headache Diseases 0.000 claims description 6
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 6
• 206010043269 Tension headache Diseases 0.000 claims description 6
• 208000008548 Tension-Type Headache Diseases 0.000 claims description 6
• 230000036506 anxiety Effects 0.000 claims description 6
• 208000011775 arteriosclerosis disease Diseases 0.000 claims description 6
• 230000036772 blood pressure Effects 0.000 claims description 6
• 150000001638 boron Chemical class 0.000 claims description 6
• 208000018912 cluster headache syndrome Diseases 0.000 claims description 6
• 125000005265 dialkylamine group Chemical group 0.000 claims description 6
• 239000003814 drug Substances 0.000 claims description 6
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
• 239000011593 sulfur Substances 0.000 claims description 6
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
• UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 claims description 5
• 208000024827 Alzheimer disease Diseases 0.000 claims description 5
• 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 5
• 208000019695 Migraine disease Diseases 0.000 claims description 5
• 241001674048 Phthiraptera Species 0.000 claims description 5
• 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 5
• 208000005298 acute pain Diseases 0.000 claims description 5
• 229910052785 arsenic Inorganic materials 0.000 claims description 5
• RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 claims description 5
• 229910052801 chlorine Inorganic materials 0.000 claims description 5
• 230000013872 defecation Effects 0.000 claims description 5
• 230000003111 delayed effect Effects 0.000 claims description 5
• 206010014599 encephalitis Diseases 0.000 claims description 5
• 230000027939 micturition Effects 0.000 claims description 5
• 206010027599 migraine Diseases 0.000 claims description 5
• 239000008267 milk Substances 0.000 claims description 5
• NCYVXEGFNDZQCU-UHFFFAOYSA-N nikethamide Chemical compound CCN(CC)C(=O)C1=CC=CN=C1 NCYVXEGFNDZQCU-UHFFFAOYSA-N 0.000 claims description 5
• 201000008482 osteoarthritis Diseases 0.000 claims description 5
• 210000002307 prostate Anatomy 0.000 claims description 5
• 230000011514 reflex Effects 0.000 claims description 5
• 230000000241 respiratory effect Effects 0.000 claims description 5
• 125000004426 substituted alkynyl group Chemical group 0.000 claims description 5
• ODGIMMLDVSWADK-UHFFFAOYSA-N 4-trifluoromethylaniline Chemical compound NC1=CC=C(C(F)(F)F)C=C1 ODGIMMLDVSWADK-UHFFFAOYSA-N 0.000 claims description 4
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical group [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 4
• 206010069632 Bladder dysfunction Diseases 0.000 claims description 4
• 101100167062 Caenorhabditis elegans chch-3 gene Proteins 0.000 claims description 4
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
• 208000000094 Chronic Pain Diseases 0.000 claims description 4
• 208000014540 Functional gastrointestinal disease Diseases 0.000 claims description 4
• 206010020751 Hypersensitivity Diseases 0.000 claims description 4
• 206010021639 Incontinence Diseases 0.000 claims description 4
• UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical group C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims description 4
• 150000003973 alkyl amines Chemical class 0.000 claims description 4
• 125000004414 alkyl thio group Chemical group 0.000 claims description 4
• 230000007815 allergy Effects 0.000 claims description 4
• 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 4
• 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 4
• 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 4
• 125000005605 benzo group Chemical group 0.000 claims description 4
• 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 4
• 150000001602 bicycloalkyls Chemical group 0.000 claims description 4
• 201000007637 bowel dysfunction Diseases 0.000 claims description 4
• 150000004985 diamines Chemical class 0.000 claims description 4
• 235000005911 diet Nutrition 0.000 claims description 4
• 235000013336 milk Nutrition 0.000 claims description 4
• 210000004080 milk Anatomy 0.000 claims description 4
• 201000006417 multiple sclerosis Diseases 0.000 claims description 4
• 201000001119 neuropathy Diseases 0.000 claims description 4
• 208000033808 peripheral neuropathy Diseases 0.000 claims description 4
• 230000000699 topical effect Effects 0.000 claims description 4
• 208000020925 Bipolar disease Diseases 0.000 claims description 3
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
• 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 3
• 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 3
• 201000004681 Psoriasis Diseases 0.000 claims description 3
• 206010039085 Rhinitis allergic Diseases 0.000 claims description 3
• 206010046543 Urinary incontinence Diseases 0.000 claims description 3
• 150000001335 aliphatic alkanes Chemical class 0.000 claims description 3
• 125000002877 alkyl aryl group Chemical group 0.000 claims description 3
• 230000000172 allergic effect Effects 0.000 claims description 3
• 201000010105 allergic rhinitis Diseases 0.000 claims description 3
• 231100000360 alopecia Toxicity 0.000 claims description 3
• 208000010668 atopic eczema Diseases 0.000 claims description 3
• 210000000988 bone and bone Anatomy 0.000 claims description 3
• 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims description 3
• 230000019771 cognition Effects 0.000 claims description 3
• 208000010877 cognitive disease Diseases 0.000 claims description 3
• WVIIMZNLDWSIRH-UHFFFAOYSA-N cyclohexylcyclohexane Chemical group C1CCCCC1C1CCCCC1 WVIIMZNLDWSIRH-UHFFFAOYSA-N 0.000 claims description 3
• 230000037213 diet Effects 0.000 claims description 3
• 208000035475 disorder Diseases 0.000 claims description 3
• 229940079593 drug Drugs 0.000 claims description 3
• 208000027866 inflammatory disease Diseases 0.000 claims description 3
• 125000006217 methyl sulfide group Chemical group [H]C([H])([H])S* 0.000 claims description 3
• 230000003959 neuroinflammation Effects 0.000 claims description 3
• 125000000714 pyrimidinyl group Chemical group 0.000 claims description 3
• MJTZVJGPTNTIIY-UHFFFAOYSA-N 2-(methoxymethyl)pyrido[3,4-d]pyrimidin-4-amine Chemical compound C1=CN=CC2=NC(COC)=NC(N)=C21 MJTZVJGPTNTIIY-UHFFFAOYSA-N 0.000 claims description 2
• UQRONKZLYKUEMO-UHFFFAOYSA-N 4-methyl-1-(2,4,6-trimethylphenyl)pent-4-en-2-one Chemical group CC(=C)CC(=O)Cc1c(C)cc(C)cc1C UQRONKZLYKUEMO-UHFFFAOYSA-N 0.000 claims description 2
• 206010063409 Acarodermatitis Diseases 0.000 claims description 2
• 206010026749 Mania Diseases 0.000 claims description 2
• 241000447727 Scabies Species 0.000 claims description 2
• PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 claims description 2
• KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 claims description 2
• 125000004947 alkyl aryl amino group Chemical group 0.000 claims description 2
• 229910052786 argon Inorganic materials 0.000 claims description 2
• IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 claims description 2
• 230000003796 beauty Effects 0.000 claims description 2
• 150000002148 esters Chemical class 0.000 claims description 2
• 125000006125 ethylsulfonyl group Chemical group 0.000 claims description 2
• 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims description 2
• 208000005687 scabies Diseases 0.000 claims description 2
• 235000021286 stilbenes Nutrition 0.000 claims description 2
• 239000004575 stone Substances 0.000 claims description 2
• 125000000565 sulfonamide group Chemical group 0.000 claims description 2
• 208000011580 syndromic disease Diseases 0.000 claims description 2
• 230000008733 trauma Effects 0.000 claims description 2
• 125000004385 trihaloalkyl group Chemical group 0.000 claims description 2
• 206010029240 Neuritis Diseases 0.000 claims 4
• 150000002220 fluorenes Chemical class 0.000 claims 4
• 230000007794 irritation Effects 0.000 claims 4
• SNQSGKQEGKHJCZ-UHFFFAOYSA-N 1,3-dimethylisoquinoline Chemical compound C1=CC=C2C(C)=NC(C)=CC2=C1 SNQSGKQEGKHJCZ-UHFFFAOYSA-N 0.000 claims 2
• UUFQTNFCRMXOAE-UHFFFAOYSA-N 1-methylmethylene Chemical compound C[CH] UUFQTNFCRMXOAE-UHFFFAOYSA-N 0.000 claims 2
• 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
• WLGKHIWFAKYQCU-UHFFFAOYSA-N 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-amine Chemical compound C1NCCC2=C1N=CN=C2N WLGKHIWFAKYQCU-UHFFFAOYSA-N 0.000 claims 2
• 208000005171 Dysmenorrhea Diseases 0.000 claims 2
• KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims 2
• 208000005392 Spasm Diseases 0.000 claims 2
• 125000004267 aziridin-2-yl group Chemical group [H]N1C([H])([H])C1([H])* 0.000 claims 2
• FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 claims 2
• 229910052707 ruthenium Inorganic materials 0.000 claims 2
• SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical group COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 claims 1
• QCCDPXJVHZVWBR-UHFFFAOYSA-N 1,4,4-trimethyl-2,3,4a,5-tetrahydroquinoline Chemical compound CN1CCC(C2CC=CC=C12)(C)C QCCDPXJVHZVWBR-UHFFFAOYSA-N 0.000 claims 1
• MOQPEGHHZLRXFB-UHFFFAOYSA-N 1-tert-butylpyrene Chemical compound C1=C2C(C(C)(C)C)=CC=C(C=C3)C2=C2C3=CC=CC2=C1 MOQPEGHHZLRXFB-UHFFFAOYSA-N 0.000 claims 1
• PDQRQJVPEFGVRK-UHFFFAOYSA-N 2,1,3-benzothiadiazole Chemical compound C1=CC=CC2=NSN=C21 PDQRQJVPEFGVRK-UHFFFAOYSA-N 0.000 claims 1
• YCWRFIYBUQBHJI-UHFFFAOYSA-N 2-(4-aminophenyl)acetonitrile Chemical group NC1=CC=C(CC#N)C=C1 YCWRFIYBUQBHJI-UHFFFAOYSA-N 0.000 claims 1
• UJJMLGJZQGGQAZ-UHFFFAOYSA-N 2-(fluoromethyl)pyridine Chemical compound FCC1=CC=CC=N1 UJJMLGJZQGGQAZ-UHFFFAOYSA-N 0.000 claims 1
• SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical class C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 claims 1
• GLOUBWDXYNRFKP-UHFFFAOYSA-N 7-(3-methylsulfonylpyridin-2-yl)-n-[6-(trifluoromethyl)pyridin-3-yl]-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-4-amine Chemical compound CS(=O)(=O)C1=CC=CN=C1N1CC(N=CN=C2NC=3C=NC(=CC=3)C(F)(F)F)=C2CC1 GLOUBWDXYNRFKP-UHFFFAOYSA-N 0.000 claims 1
• SVLPLWRJHQICAY-UHFFFAOYSA-N 7-phenyl-n-[4-(trifluoromethyl)phenyl]-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-4-amine Chemical compound C1=CC(C(F)(F)F)=CC=C1NC1=NC=NC2=C1CCN(C=1C=CC=CC=1)C2 SVLPLWRJHQICAY-UHFFFAOYSA-N 0.000 claims 1
• 102100037651 AP-2 complex subunit sigma Human genes 0.000 claims 1
• 241000251468 Actinopterygii Species 0.000 claims 1
• 208000031295 Animal disease Diseases 0.000 claims 1
• 241000220438 Arachis Species 0.000 claims 1
• 235000003911 Arachis Nutrition 0.000 claims 1
• 206010006482 Bronchospasm Diseases 0.000 claims 1
• 206010068065 Burning mouth syndrome Diseases 0.000 claims 1
• 206010008334 Cervicobrachial syndrome Diseases 0.000 claims 1
• 241000088885 Chlorops Species 0.000 claims 1
• 206010010904 Convulsion Diseases 0.000 claims 1
• 206010013935 Dysmenorrhoea Diseases 0.000 claims 1
• 208000030814 Eating disease Diseases 0.000 claims 1
• 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
• 206010016717 Fistula Diseases 0.000 claims 1
• 208000005577 Gastroenteritis Diseases 0.000 claims 1
• 241000238631 Hexapoda Species 0.000 claims 1
• 101000806914 Homo sapiens AP-2 complex subunit sigma Proteins 0.000 claims 1
• 208000019693 Lung disease Diseases 0.000 claims 1
• QECVIPBZOPUTRD-UHFFFAOYSA-N N=S(=O)=O Chemical group N=S(=O)=O QECVIPBZOPUTRD-UHFFFAOYSA-N 0.000 claims 1
• 206010068106 Occipital neuralgia Diseases 0.000 claims 1
• 206010036105 Polyneuropathy Diseases 0.000 claims 1
• 208000034189 Sclerosis Diseases 0.000 claims 1
• 241000543375 Sideroxylon Species 0.000 claims 1
• 208000004078 Snake Bites Diseases 0.000 claims 1
• 208000003589 Spider Bites Diseases 0.000 claims 1
• 206010041899 Stab wound Diseases 0.000 claims 1
• DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 1
• CZKYLWACZPRYOR-UHFFFAOYSA-N [S].OS(O)(=O)=O Chemical compound [S].OS(O)(=O)=O CZKYLWACZPRYOR-UHFFFAOYSA-N 0.000 claims 1
• UNLRVSBRNJYNHN-UHFFFAOYSA-N [cyano-(3-phenoxyphenyl)methyl] 2-(4-chlorophenyl)-3-methylbutanoate;dimethoxy-(4-nitrophenoxy)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)OC1=CC=C([N+]([O-])=O)C=C1.C=1C=C(Cl)C=CC=1C(C(C)C)C(=O)OC(C#N)C(C=1)=CC=CC=1OC1=CC=CC=C1 UNLRVSBRNJYNHN-UHFFFAOYSA-N 0.000 claims 1
• 210000001015 abdomen Anatomy 0.000 claims 1
• AQLMHYSWFMLWBS-UHFFFAOYSA-N arsenite(1-) Chemical compound O[As](O)[O-] AQLMHYSWFMLWBS-UHFFFAOYSA-N 0.000 claims 1
• 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 1
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
• 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
• 125000005293 bicycloalkoxy group Chemical group 0.000 claims 1
• 235000010290 biphenyl Nutrition 0.000 claims 1
• 239000004305 biphenyl Substances 0.000 claims 1
• 125000006267 biphenyl group Chemical group 0.000 claims 1
• 208000025698 brain inflammatory disease Diseases 0.000 claims 1
• 230000007885 bronchoconstriction Effects 0.000 claims 1
• 230000035606 childbirth Effects 0.000 claims 1
• 239000004927 clay Substances 0.000 claims 1
• 238000002648 combination therapy Methods 0.000 claims 1
• 230000036461 convulsion Effects 0.000 claims 1
• MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 claims 1
• HIPGERBLJVVQSG-UHFFFAOYSA-N diazonio(9h-fluoren-1-yl)azanide Chemical compound C12=CC=CC=C2CC2=C1C=CC=C2N=[N+]=[N-] HIPGERBLJVVQSG-UHFFFAOYSA-N 0.000 claims 1
• 125000004212 difluorophenyl group Chemical group 0.000 claims 1
• 239000000539 dimer Substances 0.000 claims 1
• 150000002012 dioxanes Chemical class 0.000 claims 1
• 235000014632 disordered eating Nutrition 0.000 claims 1
• 206010013990 dysuria Diseases 0.000 claims 1
• 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
• 230000003890 fistula Effects 0.000 claims 1
• 125000001207 fluorophenyl group Chemical group 0.000 claims 1
• 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 1
• 230000003400 hallucinatory effect Effects 0.000 claims 1
• 125000001188 haloalkyl group Chemical group 0.000 claims 1
• 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
• 125000001041 indolyl group Chemical group 0.000 claims 1
• 230000003871 intestinal function Effects 0.000 claims 1
• 230000005722 itchiness Effects 0.000 claims 1
• 206010025482 malaise Diseases 0.000 claims 1
• 230000005906 menstruation Effects 0.000 claims 1
• 210000001259 mesencephalon Anatomy 0.000 claims 1
• 210000003205 muscle Anatomy 0.000 claims 1
• SLFVYFOEHHLHDW-UHFFFAOYSA-N n-(trifluoromethyl)aniline Chemical group FC(F)(F)NC1=CC=CC=C1 SLFVYFOEHHLHDW-UHFFFAOYSA-N 0.000 claims 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
• 125000001736 nosyl group Chemical group S(=O)(=O)(C1=CC=C([N+](=O)[O-])C=C1)* 0.000 claims 1
• 238000010899 nucleation Methods 0.000 claims 1
• 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 claims 1
• 208000035824 paresthesia Diseases 0.000 claims 1
• IMACFCSSMIZSPP-UHFFFAOYSA-N phenacyl chloride Chemical compound ClCC(=O)C1=CC=CC=C1 IMACFCSSMIZSPP-UHFFFAOYSA-N 0.000 claims 1
• ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 1
• YSWYYGKGAYSAOJ-UHFFFAOYSA-N phosphane Chemical compound P.P YSWYYGKGAYSAOJ-UHFFFAOYSA-N 0.000 claims 1
• 208000019629 polyneuritis Diseases 0.000 claims 1
• 230000002028 premature Effects 0.000 claims 1
• 230000002035 prolonged effect Effects 0.000 claims 1
• LYAUUZMJFWBWLA-UHFFFAOYSA-N pyrido[3,4-d]pyrimidine-2,4-diamine Chemical compound C1=CN=CC2=NC(N)=NC(N)=C21 LYAUUZMJFWBWLA-UHFFFAOYSA-N 0.000 claims 1
• VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 claims 1
• IIHQNAXFIODVDU-UHFFFAOYSA-N pyrimidine-2-carbonitrile Chemical compound N#CC1=NC=CC=N1 IIHQNAXFIODVDU-UHFFFAOYSA-N 0.000 claims 1
• 210000000664 rectum Anatomy 0.000 claims 1
• 230000029058 respiratory gaseous exchange Effects 0.000 claims 1
• 238000005096 rolling process Methods 0.000 claims 1
• 230000001568 sexual effect Effects 0.000 claims 1
• 235000015170 shellfish Nutrition 0.000 claims 1
• 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
• PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 claims 1
• 150000003457 sulfones Chemical class 0.000 claims 1
• RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium Chemical compound [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 claims 1
• 239000003491 tear gas Substances 0.000 claims 1
• 125000005503 thioxanyl group Chemical group 0.000 claims 1
• 230000002485 urinary effect Effects 0.000 claims 1
• 230000000670 limiting effect Effects 0.000 abstract description 7
• 230000008736 traumatic injury Effects 0.000 abstract 1
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 195
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 84
• 239000007787 solid Substances 0.000 description 80
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 78
• 239000000243 solution Substances 0.000 description 75
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 65
• 239000002904 solvent Substances 0.000 description 59
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 54
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 49
• 239000000047 product Substances 0.000 description 48
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 47
• 238000005481 NMR spectroscopy Methods 0.000 description 43
• 125000001424 substituent group Chemical group 0.000 description 41
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 39
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 39
• 229910052938 sodium sulfate Inorganic materials 0.000 description 37
• 235000011152 sodium sulphate Nutrition 0.000 description 37
• 239000012267 brine Substances 0.000 description 35
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 35
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 33
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 32
• 239000000126 substance Substances 0.000 description 30
• 239000000843 powder Substances 0.000 description 29
• 239000011541 reaction mixture Substances 0.000 description 25
• 238000012360 testing method Methods 0.000 description 25
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 24
• 239000012044 organic layer Substances 0.000 description 24
• 108090000862 Ion Channels Proteins 0.000 description 23
• 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 23
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
• ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Natural products CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 22
• 230000005764 inhibitory process Effects 0.000 description 19
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 16
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 16
• 125000004432 carbon atom Chemical group C* 0.000 description 16
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
• 125000005309 thioalkoxy group Chemical group 0.000 description 15
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 14
• 239000003153 chemical reaction reagent Substances 0.000 description 14
• 235000019441 ethanol Nutrition 0.000 description 14
• 238000003786 synthesis reaction Methods 0.000 description 14
• 210000004027 cell Anatomy 0.000 description 13
• 238000004440 column chromatography Methods 0.000 description 13
• 239000003921 oil Substances 0.000 description 13
• 235000017557 sodium bicarbonate Nutrition 0.000 description 12
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 12
• FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 12
• 125000005346 substituted cycloalkyl group Chemical group 0.000 description 12
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
• 238000010438 heat treatment Methods 0.000 description 11
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
• 108091006146 Channels Proteins 0.000 description 10
• 125000003342 alkenyl group Chemical group 0.000 description 10
• 239000000463 material Substances 0.000 description 10
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 10
• 125000005415 substituted alkoxy group Chemical group 0.000 description 10
• 125000005296 thioaryloxy group Chemical group 0.000 description 10
• PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 9
• 239000012298 atmosphere Substances 0.000 description 9
• 125000004429 atom Chemical group 0.000 description 9
• 238000009472 formulation Methods 0.000 description 9
• 210000000287 oocyte Anatomy 0.000 description 9
• 229920006395 saturated elastomer Polymers 0.000 description 9
• 239000011734 sodium Substances 0.000 description 9
• 238000003756 stirring Methods 0.000 description 9
• MAKFMOSBBNKPMS-UHFFFAOYSA-N 2,3-dichloropyridine Chemical compound ClC1=CC=CN=C1Cl MAKFMOSBBNKPMS-UHFFFAOYSA-N 0.000 description 8
• IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 8
• 241000282414 Homo sapiens Species 0.000 description 8
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 8
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
• 241001465754 Metazoa Species 0.000 description 8
• 241000700159 Rattus Species 0.000 description 8
• WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 8
• 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 8
• 238000004458 analytical method Methods 0.000 description 8
• 239000007864 aqueous solution Substances 0.000 description 8
• 230000002401 inhibitory effect Effects 0.000 description 8
• 238000000746 purification Methods 0.000 description 8
• BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 8
• 102000005962 receptors Human genes 0.000 description 8
• 108020003175 receptors Proteins 0.000 description 8
• 230000004044 response Effects 0.000 description 8
• 238000010898 silica gel chromatography Methods 0.000 description 8
• 229910052708 sodium Inorganic materials 0.000 description 8
• 125000003396 thiol group Chemical group [H]S* 0.000 description 8
• BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 7
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
• 230000015572 biosynthetic process Effects 0.000 description 7
• 229910001424 calcium ion Inorganic materials 0.000 description 7
• 238000004587 chromatography analysis Methods 0.000 description 7
• 125000004122 cyclic group Chemical group 0.000 description 7
• 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 7
• 230000000694 effects Effects 0.000 description 7
• 239000003925 fat Substances 0.000 description 7
• 238000007429 general method Methods 0.000 description 7
• LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 description 7
• 230000002829 reductive effect Effects 0.000 description 7
• 229910000029 sodium carbonate Inorganic materials 0.000 description 7
• 230000000638 stimulation Effects 0.000 description 7
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
• 108010062740 TRPV Cation Channels Proteins 0.000 description 6
• 150000001409 amidines Chemical class 0.000 description 6
• QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 6
• 208000006673 asthma Diseases 0.000 description 6
• 239000000969 carrier Substances 0.000 description 6
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
• 229940125904 compound 1 Drugs 0.000 description 6
• OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 6
• 239000013078 crystal Substances 0.000 description 6
• 238000000502 dialysis Methods 0.000 description 6
• 239000000284 extract Substances 0.000 description 6
• 239000000706 filtrate Substances 0.000 description 6
• 150000002430 hydrocarbons Chemical class 0.000 description 6
• 239000012528 membrane Substances 0.000 description 6
• 239000012071 phase Substances 0.000 description 6
• YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 6
• 229910052700 potassium Inorganic materials 0.000 description 6
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
• 239000002994 raw material Substances 0.000 description 6
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
• 208000004454 Hyperalgesia Diseases 0.000 description 5
• 229930194542 Keto Natural products 0.000 description 5
• 239000005909 Kieselgur Substances 0.000 description 5
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
• 239000000556 agonist Substances 0.000 description 5
• SKOLWUPSYHWYAM-UHFFFAOYSA-N carbonodithioic O,S-acid Chemical compound SC(S)=O SKOLWUPSYHWYAM-UHFFFAOYSA-N 0.000 description 5
• 239000003795 chemical substances by application Substances 0.000 description 5
• 230000001684 chronic effect Effects 0.000 description 5
• 238000001914 filtration Methods 0.000 description 5
• 210000002683 foot Anatomy 0.000 description 5
• 230000006870 function Effects 0.000 description 5
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical group I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 5
• 239000004615 ingredient Substances 0.000 description 5
• 238000001990 intravenous administration Methods 0.000 description 5
• 125000000468 ketone group Chemical group 0.000 description 5
• NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 5
• 238000002360 preparation method Methods 0.000 description 5
• 239000003826 tablet Substances 0.000 description 5
• 125000004001 thioalkyl group Chemical group 0.000 description 5
• 125000005323 thioketone group Chemical group 0.000 description 5
• LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 4
• 108091005462 Cation channels Proteins 0.000 description 4
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
• 241000282412 Homo Species 0.000 description 4
• OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
• UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 4
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
• 239000004480 active ingredient Substances 0.000 description 4
• 125000006598 aminocarbonylamino group Chemical class 0.000 description 4
• 239000005557 antagonist Substances 0.000 description 4
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
• 239000008280 blood Substances 0.000 description 4
• 210000004369 blood Anatomy 0.000 description 4
• 239000002775 capsule Substances 0.000 description 4
• 229910002091 carbon monoxide Inorganic materials 0.000 description 4
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
• 230000000747 cardiac effect Effects 0.000 description 4
• 239000012043 crude product Substances 0.000 description 4
• 239000002552 dosage form Substances 0.000 description 4
• 231100000673 dose–response relationship Toxicity 0.000 description 4
• GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 4
• 239000006260 foam Substances 0.000 description 4
• 125000000524 functional group Chemical group 0.000 description 4
• 125000004475 heteroaralkyl group Chemical group 0.000 description 4
• 238000002347 injection Methods 0.000 description 4
• 239000007924 injection Substances 0.000 description 4
• 150000002500 ions Chemical class 0.000 description 4
• 150000002576 ketones Chemical class 0.000 description 4
• 239000007788 liquid Substances 0.000 description 4
• 239000000314 lubricant Substances 0.000 description 4
• 239000011777 magnesium Substances 0.000 description 4
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
• 235000019341 magnesium sulphate Nutrition 0.000 description 4
• 210000002569 neuron Anatomy 0.000 description 4
• 239000012299 nitrogen atmosphere Substances 0.000 description 4
• 239000008055 phosphate buffer solution Substances 0.000 description 4
• XRBCRPZXSCBRTK-UHFFFAOYSA-N phosphonous acid Chemical group OPO XRBCRPZXSCBRTK-UHFFFAOYSA-N 0.000 description 4
• 239000011591 potassium Substances 0.000 description 4
• 125000006239 protecting group Chemical group 0.000 description 4
• 230000001953 sensory effect Effects 0.000 description 4
• 235000009518 sodium iodide Nutrition 0.000 description 4
• LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
• 239000007858 starting material Substances 0.000 description 4
• 210000000130 stem cell Anatomy 0.000 description 4
• UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 4
• ZCZVGQCBSJLDDS-UHFFFAOYSA-N 1,2,3,4-tetrahydro-1,8-naphthyridine Chemical compound C1=CC=C2CCCNC2=N1 ZCZVGQCBSJLDDS-UHFFFAOYSA-N 0.000 description 3
• WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
• WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
• 101150041968 CDC13 gene Proteins 0.000 description 3
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
• 102000034573 Channels Human genes 0.000 description 3
• BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical class OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
• 108010010803 Gelatin Proteins 0.000 description 3
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
• FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
• AFBPFSWMIHJQDM-UHFFFAOYSA-N N-methylaniline Chemical compound CNC1=CC=CC=C1 AFBPFSWMIHJQDM-UHFFFAOYSA-N 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 235000021355 Stearic acid Nutrition 0.000 description 3
• 102000011040 TRPV Cation Channels Human genes 0.000 description 3
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 3
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
• 102100029613 Transient receptor potential cation channel subfamily V member 1 Human genes 0.000 description 3
• HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
• 208000027418 Wounds and injury Diseases 0.000 description 3
• 230000036982 action potential Effects 0.000 description 3
• VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 3
• 210000004556 brain Anatomy 0.000 description 3
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
• 239000011575 calcium Substances 0.000 description 3
• 229910052791 calcium Inorganic materials 0.000 description 3
• 150000001768 cations Chemical class 0.000 description 3
• 210000003169 central nervous system Anatomy 0.000 description 3
• 235000013339 cereals Nutrition 0.000 description 3
• 230000008859 change Effects 0.000 description 3
• USJRLGNYCQWLPF-UHFFFAOYSA-N chlorophosphane Chemical compound ClP USJRLGNYCQWLPF-UHFFFAOYSA-N 0.000 description 3
• 238000001816 cooling Methods 0.000 description 3
• 239000003085 diluting agent Substances 0.000 description 3
• WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 description 3
• 125000004494 ethyl ester group Chemical group 0.000 description 3
• 229910052731 fluorine Inorganic materials 0.000 description 3
• 239000008273 gelatin Substances 0.000 description 3
• 229920000159 gelatin Polymers 0.000 description 3
• 235000019322 gelatine Nutrition 0.000 description 3
• 235000011852 gelatine desserts Nutrition 0.000 description 3
• 238000004128 high performance liquid chromatography Methods 0.000 description 3
• 229940071870 hydroiodic acid Drugs 0.000 description 3
• 230000001965 increasing effect Effects 0.000 description 3
• 230000003834 intracellular effect Effects 0.000 description 3
• 239000010410 layer Substances 0.000 description 3
• 239000011159 matrix material Substances 0.000 description 3
• 229910021645 metal ion Inorganic materials 0.000 description 3
• 230000000926 neurological effect Effects 0.000 description 3
• 230000007823 neuropathy Effects 0.000 description 3
• 238000006386 neutralization reaction Methods 0.000 description 3
• 125000004433 nitrogen atom Chemical group N* 0.000 description 3
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
• 239000002674 ointment Substances 0.000 description 3
• 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 3
• 229910052763 palladium Inorganic materials 0.000 description 3
• XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 3
• 239000002504 physiological saline solution Substances 0.000 description 3
• 229910000027 potassium carbonate Inorganic materials 0.000 description 3
• 235000018102 proteins Nutrition 0.000 description 3
• 102000004169 proteins and genes Human genes 0.000 description 3
• 108090000623 proteins and genes Proteins 0.000 description 3
• VNFGDCQZPRUFQD-UHFFFAOYSA-N pyrido[3,4-d]pyrimidin-2-amine Chemical compound C1=CN=CC2=NC(N)=NC=C21 VNFGDCQZPRUFQD-UHFFFAOYSA-N 0.000 description 3
• 239000012266 salt solution Substances 0.000 description 3
• 239000007921 spray Substances 0.000 description 3
• 238000010561 standard procedure Methods 0.000 description 3
• 239000008117 stearic acid Chemical group 0.000 description 3
• 239000012730 sustained-release form Substances 0.000 description 3
• 230000001225 therapeutic effect Effects 0.000 description 3
• 238000004809 thin layer chromatography Methods 0.000 description 3
• 210000001519 tissue Anatomy 0.000 description 3
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
• 229930195735 unsaturated hydrocarbon Natural products 0.000 description 3
• SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
• ZHXBUGVDYHSLCT-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrido[3,4-d]pyrimidin-4-amine Chemical compound N1=CC=C2C(N)NCNC2=C1 ZHXBUGVDYHSLCT-UHFFFAOYSA-N 0.000 description 2
• QRLLENCJWMWNCY-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrido[3,4-d]pyrimidine Chemical compound C1=NC=C2NCNCC2=C1 QRLLENCJWMWNCY-UHFFFAOYSA-N 0.000 description 2
• YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 2
• FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 2
• LUBJCRLGQSPQNN-UHFFFAOYSA-N 1-Phenylurea Chemical compound NC(=O)NC1=CC=CC=C1 LUBJCRLGQSPQNN-UHFFFAOYSA-N 0.000 description 2
• FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
• RMSGQZDGSZOJMU-UHFFFAOYSA-N 1-butyl-2-phenylbenzene Chemical group CCCCC1=CC=CC=C1C1=CC=CC=C1 RMSGQZDGSZOJMU-UHFFFAOYSA-N 0.000 description 2
• YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
• ZJOXWRFJOUWUKX-GOSISDBHSA-N 2-[[4-[(3R)-1-oxo-3,4-dihydroisochromene-3-carbonyl]piperazin-1-yl]methyl]-5,6,7,8-tetrahydro-3H-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound C1CCCC2=C1SC1=C2C(=O)NC(CN2CCN(CC2)C([C@@H]2OC(=O)C3=CC=CC=C3C2)=O)=N1 ZJOXWRFJOUWUKX-GOSISDBHSA-N 0.000 description 2
• KRGYYSGWNZRJPY-UHFFFAOYSA-N 2-chloro-3-methylsulfonylpyridine Chemical compound CS(=O)(=O)C1=CC=CN=C1Cl KRGYYSGWNZRJPY-UHFFFAOYSA-N 0.000 description 2
• CZYGEEHJMWIINK-UHFFFAOYSA-N 2-methylsulfanylpyrido[3,4-d]pyrimidin-4-amine Chemical compound C1=CN=CC2=NC(SC)=NC(N)=C21 CZYGEEHJMWIINK-UHFFFAOYSA-N 0.000 description 2
• VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 2
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
• NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
• XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
• NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical class NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 2
• 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
• WRDWWAVNELMWAM-UHFFFAOYSA-N 4-tert-butylaniline Chemical compound CC(C)(C)C1=CC=C(N)C=C1 WRDWWAVNELMWAM-UHFFFAOYSA-N 0.000 description 2
• UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
• 108010017384 Blood Proteins Proteins 0.000 description 2
• 102000004506 Blood Proteins Human genes 0.000 description 2
• KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
• 240000008574 Capsicum frutescens Species 0.000 description 2
• RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
• 229910004039 HBF4 Inorganic materials 0.000 description 2
• 208000035154 Hyperesthesia Diseases 0.000 description 2
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
• JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
• GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
• BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• 102000004257 Potassium Channel Human genes 0.000 description 2
• WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
• DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
• 108010025083 TRPV1 receptor Proteins 0.000 description 2
• SQFPKRNUGBRTAR-UHFFFAOYSA-N acephenanthrylene Chemical group C1=CC(C=C2)=C3C2=CC2=CC=CC=C2C3=C1 SQFPKRNUGBRTAR-UHFFFAOYSA-N 0.000 description 2
• YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 2
• DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
• 125000002252 acyl group Chemical class 0.000 description 2
• MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical class [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 2
• 230000000202 analgesic effect Effects 0.000 description 2
• 229940121363 anti-inflammatory agent Drugs 0.000 description 2
• 239000002260 anti-inflammatory agent Substances 0.000 description 2
• 150000004982 aromatic amines Chemical class 0.000 description 2
• 230000005784 autoimmunity Effects 0.000 description 2
• 210000003050 axon Anatomy 0.000 description 2
• HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 2
• HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 239000004202 carbamide Substances 0.000 description 2
• BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
• 150000001804 chlorine Chemical class 0.000 description 2
• 235000015165 citric acid Nutrition 0.000 description 2
• 238000009833 condensation Methods 0.000 description 2
• 230000005494 condensation Effects 0.000 description 2
• 239000006071 cream Substances 0.000 description 2
• GCIDAUVMQWKJLE-UHFFFAOYSA-N cyclohexane;1,4-dioxane Chemical compound C1CCCCC1.C1COCCO1 GCIDAUVMQWKJLE-UHFFFAOYSA-N 0.000 description 2
• 230000006378 damage Effects 0.000 description 2
• 238000000354 decomposition reaction Methods 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 238000010586 diagram Methods 0.000 description 2
• DIXBSCZRIZDQGC-UHFFFAOYSA-N diaziridine Chemical compound C1NN1 DIXBSCZRIZDQGC-UHFFFAOYSA-N 0.000 description 2
• 238000005516 engineering process Methods 0.000 description 2
• 125000002573 ethenylidene group Chemical group [*]=C=C([H])[H] 0.000 description 2
• 210000003414 extremity Anatomy 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• 125000001153 fluoro group Chemical group F* 0.000 description 2
• 229930195712 glutamate Natural products 0.000 description 2
• 230000000642 iatrogenic effect Effects 0.000 description 2
• 208000026278 immune system disease Diseases 0.000 description 2
• PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
• 230000004941 influx Effects 0.000 description 2
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
• AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• 239000007937 lozenge Substances 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
• 239000011976 maleic acid Substances 0.000 description 2
• 235000012054 meals Nutrition 0.000 description 2
• 238000005259 measurement Methods 0.000 description 2
• 230000028161 membrane depolarization Effects 0.000 description 2
• VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
• OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
• 125000001064 morpholinomethyl group Chemical group [H]C([H])(*)N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 description 2
• TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical group OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
• AJFDBNQQDYLMJN-UHFFFAOYSA-N n,n-diethylacetamide Chemical compound CCN(CC)C(C)=O AJFDBNQQDYLMJN-UHFFFAOYSA-N 0.000 description 2
• 230000001537 neural effect Effects 0.000 description 2
• 230000000626 neurodegenerative effect Effects 0.000 description 2
• YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical group C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 description 2
• 230000003040 nociceptive effect Effects 0.000 description 2
• 239000012038 nucleophile Substances 0.000 description 2
• GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
• TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 2
• 150000002894 organic compounds Chemical class 0.000 description 2
• 125000004043 oxo group Chemical group O=* 0.000 description 2
• 244000052769 pathogen Species 0.000 description 2
• YWAKXRMUMFPDSH-UHFFFAOYSA-N pentene Chemical compound CCCC=C YWAKXRMUMFPDSH-UHFFFAOYSA-N 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• 125000004344 phenylpropyl group Chemical group 0.000 description 2
• 108020001213 potassium channel Proteins 0.000 description 2
• 239000002244 precipitate Substances 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• PAQYIEZTLSDLQO-UHFFFAOYSA-N pyrido[3,4-d]pyrimidine Chemical compound N1=CN=C2C=NC=CC2=C1 PAQYIEZTLSDLQO-UHFFFAOYSA-N 0.000 description 2
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
• 239000000376 reactant Substances 0.000 description 2
• 208000007442 rickets Diseases 0.000 description 2
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical group OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
• 210000003296 saliva Anatomy 0.000 description 2
• 238000012216 screening Methods 0.000 description 2
• 239000011780 sodium chloride Substances 0.000 description 2
• 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
• 235000010288 sodium nitrite Nutrition 0.000 description 2
• 125000005017 substituted alkenyl group Chemical group 0.000 description 2
• 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 2
• 238000013268 sustained release Methods 0.000 description 2
• 230000002889 sympathetic effect Effects 0.000 description 2
• 239000012085 test solution Substances 0.000 description 2
• 229930192474 thiophene Natural products 0.000 description 2
• 230000000472 traumatic effect Effects 0.000 description 2
• 208000014001 urinary system disease Diseases 0.000 description 2
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
• 229920002554 vinyl polymer Polymers 0.000 description 2
• 208000009935 visceral pain Diseases 0.000 description 2
• CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
• GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
• QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
• STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
• KWMLJOLKUYYJFJ-GASJEMHNSA-N (2xi)-D-gluco-heptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C(O)=O KWMLJOLKUYYJFJ-GASJEMHNSA-N 0.000 description 1
• GOXICVKOZJFRMB-UHFFFAOYSA-N (3-phenylphenyl)boronic acid Chemical compound OB(O)C1=CC=CC(C=2C=CC=CC=2)=C1 GOXICVKOZJFRMB-UHFFFAOYSA-N 0.000 description 1
• BIWQNIMLAISTBV-UHFFFAOYSA-N (4-methylphenyl)boronic acid Chemical compound CC1=CC=C(B(O)O)C=C1 BIWQNIMLAISTBV-UHFFFAOYSA-N 0.000 description 1
• MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
• KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
• UUSUFQUCLACDTA-UHFFFAOYSA-N 1,2-dihydropyrene Chemical compound C1=CC=C2C=CC3=CCCC4=CC=C1C2=C43 UUSUFQUCLACDTA-UHFFFAOYSA-N 0.000 description 1
• BGJSXRVXTHVRSN-UHFFFAOYSA-N 1,3,5-trioxane Chemical compound C1OCOCO1 BGJSXRVXTHVRSN-UHFFFAOYSA-N 0.000 description 1
• IXTNDEVVXTYVHI-UHFFFAOYSA-N 1,4-dioxan-2-amine Chemical compound NC1COCCO1 IXTNDEVVXTYVHI-UHFFFAOYSA-N 0.000 description 1
• MSULIXYJBOXXDR-UHFFFAOYSA-N 1-chloroethyl 2-chloroacetate Chemical compound CC(Cl)OC(=O)CCl MSULIXYJBOXXDR-UHFFFAOYSA-N 0.000 description 1
• GEUYACYJMUQXCF-UHFFFAOYSA-N 1-ethyl-2-(2-phenylethenyl)benzene Chemical compound CCC1=CC=CC=C1C=CC1=CC=CC=C1 GEUYACYJMUQXCF-UHFFFAOYSA-N 0.000 description 1
• 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 description 1
• PEBXLTUWFWEWGV-UHFFFAOYSA-N 1-methyl-2-(2-phenylethenyl)benzene Chemical compound CC1=CC=CC=C1C=CC1=CC=CC=C1 PEBXLTUWFWEWGV-UHFFFAOYSA-N 0.000 description 1
• PUFWGUZSDHANBX-UHFFFAOYSA-N 1-phenyl-9h-fluorene Chemical compound C=12CC3=CC=CC=C3C2=CC=CC=1C1=CC=CC=C1 PUFWGUZSDHANBX-UHFFFAOYSA-N 0.000 description 1
• 238000005160 1H NMR spectroscopy Methods 0.000 description 1
• KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
• BNYCHCAYYYRJSH-UHFFFAOYSA-N 1h-pyrazole-5-carboxamide Chemical compound NC(=O)C1=CC=NN1 BNYCHCAYYYRJSH-UHFFFAOYSA-N 0.000 description 1
• AKWIAIDKXNKXDI-UHFFFAOYSA-N 1h-pyrrole-3-carboxamide Chemical compound NC(=O)C=1C=CNC=1 AKWIAIDKXNKXDI-UHFFFAOYSA-N 0.000 description 1
• BIEFDNUEROKZRA-UHFFFAOYSA-N 2-(2-phenylethenyl)aniline Chemical compound NC1=CC=CC=C1C=CC1=CC=CC=C1 BIEFDNUEROKZRA-UHFFFAOYSA-N 0.000 description 1
• VXDPOGVDHHJTDY-UHFFFAOYSA-N 2-(4-aminophenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)C1=CC=C(N)C=C1 VXDPOGVDHHJTDY-UHFFFAOYSA-N 0.000 description 1
• ATRQECRSCHYSNP-UHFFFAOYSA-N 2-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=CC=N1 ATRQECRSCHYSNP-UHFFFAOYSA-N 0.000 description 1
• DBCKFCWHCNWZTG-UHFFFAOYSA-N 2-[bis(fluorosulfonyl)amino]benzenesulfonyl fluoride Chemical compound FS(=O)(=O)C1=C(N(S(=O)(=O)F)S(=O)(=O)F)C=CC=C1 DBCKFCWHCNWZTG-UHFFFAOYSA-N 0.000 description 1
• UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
• ULFQKXHBXXLEFC-UHFFFAOYSA-N 2-benzyl-9h-fluorene Chemical compound C=1C=C(C2=CC=CC=C2C2)C2=CC=1CC1=CC=CC=C1 ULFQKXHBXXLEFC-UHFFFAOYSA-N 0.000 description 1
• OVHUHICFIPPLCB-UHFFFAOYSA-N 2-bromo-1-cyclohexyl-9h-fluorene Chemical compound BrC1=CC=C(C2=CC=CC=C2C2)C2=C1C1CCCCC1 OVHUHICFIPPLCB-UHFFFAOYSA-N 0.000 description 1
• RXATZPCCMYMPME-UHFFFAOYSA-N 2-chloro-3-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=CN=C1Cl RXATZPCCMYMPME-UHFFFAOYSA-N 0.000 description 1
• KRIGAYSDVBBXLW-UHFFFAOYSA-N 2-chloro-3-ethylsulfonylpyridine Chemical compound CCS(=O)(=O)C1=CC=CN=C1Cl KRIGAYSDVBBXLW-UHFFFAOYSA-N 0.000 description 1
• ILXBCRLDJHAPTA-UHFFFAOYSA-N 2-chloro-3-propan-2-ylsulfonylpyridine Chemical compound CC(C)S(=O)(=O)C1=CC=CN=C1Cl ILXBCRLDJHAPTA-UHFFFAOYSA-N 0.000 description 1
• SIUTWYZMSNPSIO-UHFFFAOYSA-N 2-chloroethyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OCCCl SIUTWYZMSNPSIO-UHFFFAOYSA-N 0.000 description 1
• 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
• 150000005749 2-halopyridines Chemical class 0.000 description 1
• NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
• UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical group C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
• ZMOVXTGAIFGCAY-UHFFFAOYSA-N 2-methoxypyridine Chemical compound COC1=CC=C=C[N]1 ZMOVXTGAIFGCAY-UHFFFAOYSA-N 0.000 description 1
• PCLKVJBRTCQNDU-UHFFFAOYSA-N 2-methylsulfonylpyridine Chemical compound CS(=O)(=O)C1=CC=CC=N1 PCLKVJBRTCQNDU-UHFFFAOYSA-N 0.000 description 1
• BIWLRLKFPPNXFJ-UHFFFAOYSA-N 2-methylsulfonylpyrido[3,4-d]pyrimidine Chemical compound C1=CN=CC2=NC(S(=O)(=O)C)=NC=C21 BIWLRLKFPPNXFJ-UHFFFAOYSA-N 0.000 description 1
• JBIJLHTVPXGSAM-UHFFFAOYSA-N 2-naphthylamine Chemical compound C1=CC=CC2=CC(N)=CC=C21 JBIJLHTVPXGSAM-UHFFFAOYSA-N 0.000 description 1
• UDAIGHZFMLGNDQ-UHFFFAOYSA-N 2-nitroquinoline Chemical class C1=CC=CC2=NC([N+](=O)[O-])=CC=C21 UDAIGHZFMLGNDQ-UHFFFAOYSA-N 0.000 description 1
• 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
• RWNISPVLLBWJBU-UHFFFAOYSA-N 2-sulfonyl-1h-pyridine Chemical compound O=S(=O)=C1C=CC=CN1 RWNISPVLLBWJBU-UHFFFAOYSA-N 0.000 description 1
• IFCSRTYDKIBLCT-UHFFFAOYSA-N 2H-1,4-benzodioxine-3,3-diamine Chemical compound NC1(COC2=C(O1)C=CC=C2)N IFCSRTYDKIBLCT-UHFFFAOYSA-N 0.000 description 1
• JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
• BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
• KSNKQSPJFRQSEI-UHFFFAOYSA-N 3,3,3-trifluoropropanoic acid Chemical compound OC(=O)CC(F)(F)F KSNKQSPJFRQSEI-UHFFFAOYSA-N 0.000 description 1
• FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
• JTZSFNHHVULOGJ-UHFFFAOYSA-N 3-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=CN=C1 JTZSFNHHVULOGJ-UHFFFAOYSA-N 0.000 description 1
• CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 1
• 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
• 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
• 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
• HZSAPNSHGPNDHF-UHFFFAOYSA-N 3-methylsulfonylpyridine Chemical compound CS(=O)(=O)C1=CC=CN=C1 HZSAPNSHGPNDHF-UHFFFAOYSA-N 0.000 description 1
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
• HLLSOEKIMZEGFV-UHFFFAOYSA-N 4-(dibutylsulfamoyl)benzoic acid Chemical compound CCCCN(CCCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 HLLSOEKIMZEGFV-UHFFFAOYSA-N 0.000 description 1
• CFQYOTZLYKJVKS-UHFFFAOYSA-N 4-[9-(4-carbamimidoylphenoxy)nonoxy]benzenecarboximidamide Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCCCCCOC1=CC=C(C(N)=N)C=C1 CFQYOTZLYKJVKS-UHFFFAOYSA-N 0.000 description 1
• JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-dimethylaminophenol Chemical compound CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 1
• 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
• VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
• KRZCOLNOCZKSDF-UHFFFAOYSA-N 4-fluoroaniline Chemical compound NC1=CC=C(F)C=C1 KRZCOLNOCZKSDF-UHFFFAOYSA-N 0.000 description 1
• 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 1
• GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 1
• 125000001318 4-trifluoromethylbenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])*)C(F)(F)F 0.000 description 1
• 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 1
• DVHCRTQZUZFLAY-UHFFFAOYSA-N 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-7-ium-4-olate Chemical compound C1NCCC2=C1N=CNC2=O DVHCRTQZUZFLAY-UHFFFAOYSA-N 0.000 description 1
• QGFYFOHMBDMGBZ-UHFFFAOYSA-N 5-[(7-chloroquinolin-4-yl)amino]-2-(diethylaminomethyl)phenol Chemical compound C1=C(O)C(CN(CC)CC)=CC=C1NC1=CC=NC2=CC(Cl)=CC=C12 QGFYFOHMBDMGBZ-UHFFFAOYSA-N 0.000 description 1
• NPBFIVINYZHYIJ-UHFFFAOYSA-N 5-phenyl-4-(trifluoromethyl)-1h-pyrazole Chemical compound C1=NNC(C=2C=CC=CC=2)=C1C(F)(F)F NPBFIVINYZHYIJ-UHFFFAOYSA-N 0.000 description 1
• IBOZOWZSXZNIHI-UHFFFAOYSA-N 6-(trifluoromethyl)pyridin-3-amine Chemical compound NC1=CC=C(C(F)(F)F)N=C1 IBOZOWZSXZNIHI-UHFFFAOYSA-N 0.000 description 1
• PDZGYMZCMUSHBP-UHFFFAOYSA-N 7-benzyl-4-chloro-2-methylsulfanyl-6,8-dihydro-5h-pyrido[3,4-d]pyrimidine Chemical compound C1C2=NC(SC)=NC(Cl)=C2CCN1CC1=CC=CC=C1 PDZGYMZCMUSHBP-UHFFFAOYSA-N 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
• 108091023037 Aptamer Proteins 0.000 description 1
• 101100030365 Arabidopsis thaliana CRR4 gene Proteins 0.000 description 1
• 241000193830 Bacillus <bacterium> Species 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• 208000014644 Brain disease Diseases 0.000 description 1
• WVWUSBHUMBREKR-UHFFFAOYSA-N C(C)(=O)OCC.C(C)(=O)O.Cl Chemical compound C(C)(=O)OCC.C(C)(=O)O.Cl WVWUSBHUMBREKR-UHFFFAOYSA-N 0.000 description 1
• QKVRCBOFIIDVND-UHFFFAOYSA-N C(N)(=N)N(C(C)=O)C(N)=N Chemical compound C(N)(=N)N(C(C)=O)C(N)=N QKVRCBOFIIDVND-UHFFFAOYSA-N 0.000 description 1
• YYCNLEJBXAKTCU-UHFFFAOYSA-N C1=C(C(=CC=C1)N1CC2=C(CC1)C(N)=NC=N2)C Chemical compound C1=C(C(=CC=C1)N1CC2=C(CC1)C(N)=NC=N2)C YYCNLEJBXAKTCU-UHFFFAOYSA-N 0.000 description 1
• JHEZGDSHTYSTEI-UHFFFAOYSA-N C1C2=CC=CC=C2C3=C1C(=C(C(=C3F)F)F)C4=CC=CC=N4 Chemical compound C1C2=CC=CC=C2C3=C1C(=C(C(=C3F)F)F)C4=CC=CC=N4 JHEZGDSHTYSTEI-UHFFFAOYSA-N 0.000 description 1
• JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
• LVRCEUVOXCJYSV-UHFFFAOYSA-N CN(C)S(=O)=O Chemical compound CN(C)S(=O)=O LVRCEUVOXCJYSV-UHFFFAOYSA-N 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• 244000025254 Cannabis sativa Species 0.000 description 1
• WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
• 235000002566 Capsicum Nutrition 0.000 description 1
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
• 239000004215 Carbon black (E152) Substances 0.000 description 1
• 241000238366 Cephalopoda Species 0.000 description 1
• 241001481710 Cerambycidae Species 0.000 description 1
• 206010008583 Chloroma Diseases 0.000 description 1
• 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Chemical group OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
• 241000790917 Dioxys <bee> Species 0.000 description 1
• 101100136092 Drosophila melanogaster peng gene Proteins 0.000 description 1
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
• 206010013954 Dysphoria Diseases 0.000 description 1
• 229910052692 Dysprosium Inorganic materials 0.000 description 1
• 108010000912 Egg Proteins Proteins 0.000 description 1
• 102000002322 Egg Proteins Human genes 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 208000032274 Encephalopathy Diseases 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• 102000004190 Enzymes Human genes 0.000 description 1
• YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
• 241001331845 Equus asinus x caballus Species 0.000 description 1
• VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
• 239000005977 Ethylene Substances 0.000 description 1
• 208000001640 Fibromyalgia Diseases 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• 108091006027 G proteins Proteins 0.000 description 1
• 102000030782 GTP binding Human genes 0.000 description 1
• 108091000058 GTP-Binding Proteins 0.000 description 1
• CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
• 229930182566 Gentamicin Natural products 0.000 description 1
• 102000018899 Glutamate Receptors Human genes 0.000 description 1
• 108010027915 Glutamate Receptors Proteins 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical group OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 241001481828 Glyptocephalus cynoglossus Species 0.000 description 1
• 208000004547 Hallucinations Diseases 0.000 description 1
• 241000519079 Hara hara Species 0.000 description 1
• 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 1
• QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 1
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
• PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
• 108010053914 KATP Channels Proteins 0.000 description 1
• 208000034693 Laceration Diseases 0.000 description 1
• 239000000232 Lipid Bilayer Substances 0.000 description 1
• 102000003820 Lipoxygenases Human genes 0.000 description 1
• 108090000128 Lipoxygenases Proteins 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 244000141359 Malus pumila Species 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• 244000246386 Mentha pulegium Species 0.000 description 1
• 235000016257 Mentha pulegium Nutrition 0.000 description 1
• 235000004357 Mentha x piperita Nutrition 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 244000294411 Mirabilis expansa Species 0.000 description 1
• 235000015429 Mirabilis expansa Nutrition 0.000 description 1
• ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
• TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Chemical group OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
• 241000699666 Mus <mouse, genus> Species 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• 208000007101 Muscle Cramp Diseases 0.000 description 1
• 208000008238 Muscle Spasticity Diseases 0.000 description 1
• 241001508687 Mustela erminea Species 0.000 description 1
• 208000000112 Myalgia Diseases 0.000 description 1
• MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
• 108010025020 Nerve Growth Factor Proteins 0.000 description 1
• 102000007072 Nerve Growth Factors Human genes 0.000 description 1
• 206010060860 Neurological symptom Diseases 0.000 description 1
• IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
• 239000006057 Non-nutritive feed additive Substances 0.000 description 1
• PCKPVGOLPKLUHR-UHFFFAOYSA-N OH-Indolxyl Natural products C1=CC=C2C(O)=CNC2=C1 PCKPVGOLPKLUHR-UHFFFAOYSA-N 0.000 description 1
• 208000011623 Obstructive Lung disease Diseases 0.000 description 1
• 244000227633 Ocotea pretiosa Species 0.000 description 1
• 235000004263 Ocotea pretiosa Nutrition 0.000 description 1
• 241000238413 Octopus Species 0.000 description 1
• 240000007594 Oryza sativa Species 0.000 description 1
• 235000007164 Oryza sativa Nutrition 0.000 description 1
• ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
• 206010033645 Pancreatitis Diseases 0.000 description 1
• 229910002666 PdCl2 Inorganic materials 0.000 description 1
• 101000579646 Penaeus vannamei Penaeidin-1 Proteins 0.000 description 1
• 229940123304 Phosphodiesterase 7 inhibitor Drugs 0.000 description 1
• 244000018633 Prunus armeniaca Species 0.000 description 1
• 235000009827 Prunus armeniaca Nutrition 0.000 description 1
• 208000003251 Pruritus Diseases 0.000 description 1
• 206010037660 Pyrexia Diseases 0.000 description 1
• LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
• IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
• 241000124033 Salix Species 0.000 description 1
• 229910052772 Samarium Inorganic materials 0.000 description 1
• 201000001880 Sexual dysfunction Diseases 0.000 description 1
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
• FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 241000610741 Tetraneuris Species 0.000 description 1
• FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
• GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
• 208000012931 Urologic disease Diseases 0.000 description 1
• 206010052428 Wound Diseases 0.000 description 1
• 241000269368 Xenopus laevis Species 0.000 description 1
• 240000008042 Zea mays Species 0.000 description 1
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
• JDPAVWAQGBGGHD-UHFFFAOYSA-N aceanthrylene Chemical group C1=CC=C2C(C=CC3=CC=C4)=C3C4=CC2=C1 JDPAVWAQGBGGHD-UHFFFAOYSA-N 0.000 description 1
• 125000004054 acenaphthylenyl group Chemical group C1(=CC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• JJHPQGFGFRPCCH-UHFFFAOYSA-N acetic acid;butane Chemical group CCCC.CC(O)=O JJHPQGFGFRPCCH-UHFFFAOYSA-N 0.000 description 1
• HXGDTGSAIMULJN-UHFFFAOYSA-N acetnaphthylene Natural products C1=CC(C=C2)=C3C2=CC=CC3=C1 HXGDTGSAIMULJN-UHFFFAOYSA-N 0.000 description 1
• OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
• 229960004373 acetylcholine Drugs 0.000 description 1
• 102000015296 acetylcholine-gated cation-selective channel activity proteins Human genes 0.000 description 1
• 108040006409 acetylcholine-gated cation-selective channel activity proteins Proteins 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
• 230000006978 adaptation Effects 0.000 description 1
• 239000000853 adhesive Substances 0.000 description 1
• 230000001070 adhesive effect Effects 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 239000000674 adrenergic antagonist Substances 0.000 description 1
• 210000003766 afferent neuron Anatomy 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 125000005262 alkoxyamine group Chemical group 0.000 description 1
• 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
• 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• 125000002947 alkylene group Chemical group 0.000 description 1
• 201000009961 allergic asthma Diseases 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
• AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• 229910000091 aluminium hydride Inorganic materials 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
• 229940035676 analgesics Drugs 0.000 description 1
• LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 description 1
• 150000008064 anhydrides Chemical class 0.000 description 1
• 150000001448 anilines Chemical class 0.000 description 1
• 239000000730 antalgic agent Substances 0.000 description 1
• 210000003056 antler Anatomy 0.000 description 1
• 235000021016 apples Nutrition 0.000 description 1
• LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 description 1
• 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
• 150000001543 aryl boronic acids Chemical class 0.000 description 1
• 125000004350 aryl cycloalkyl group Chemical group 0.000 description 1
• 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
• KNNXFYIMEYKHBZ-UHFFFAOYSA-N as-indacene Chemical compound C1=CC2=CC=CC2=C2C=CC=C21 KNNXFYIMEYKHBZ-UHFFFAOYSA-N 0.000 description 1
• PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
• RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
• 229940092714 benzenesulfonic acid Drugs 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• MTZQAGJQAFMTAQ-UHFFFAOYSA-N benzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 1
• 229940073608 benzyl chloride Drugs 0.000 description 1
• GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
• 210000000941 bile Anatomy 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 230000036765 blood level Effects 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 239000007767 bonding agent Substances 0.000 description 1
• 239000007853 buffer solution Substances 0.000 description 1
• 239000008366 buffered solution Substances 0.000 description 1
• 239000006172 buffering agent Substances 0.000 description 1
• 230000003139 buffering effect Effects 0.000 description 1
• 239000001273 butane Substances 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• DRCMAZOSEIMCHM-UHFFFAOYSA-N capsazepine Chemical compound C1C=2C=C(O)C(O)=CC=2CCCN1C(=S)NCCC1=CC=C(Cl)C=C1 DRCMAZOSEIMCHM-UHFFFAOYSA-N 0.000 description 1
• 239000001390 capsicum minimum Substances 0.000 description 1
• 125000002837 carbocyclic group Chemical group 0.000 description 1
• 150000001721 carbon Chemical group 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 238000009960 carding Methods 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 229920006184 cellulose methylcellulose Polymers 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• XTEGARKTQYYJKE-UHFFFAOYSA-N chloric acid Chemical compound OCl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-N 0.000 description 1
• 229940005991 chloric acid Drugs 0.000 description 1
• QOPVNWQGBQYBBP-UHFFFAOYSA-N chloroethyl chloroformate Chemical compound CC(Cl)OC(Cl)=O QOPVNWQGBQYBBP-UHFFFAOYSA-N 0.000 description 1
• 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 description 1
• 125000006378 chloropyridyl group Chemical group 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• ZCDOYSPFYFSLEW-UHFFFAOYSA-N chromate(2-) Chemical compound [O-][Cr]([O-])(=O)=O ZCDOYSPFYFSLEW-UHFFFAOYSA-N 0.000 description 1
• 235000017803 cinnamon Nutrition 0.000 description 1
• 210000000078 claw Anatomy 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 239000012230 colorless oil Substances 0.000 description 1
• 229940125758 compound 15 Drugs 0.000 description 1
• 229940125878 compound 36 Drugs 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 235000008504 concentrate Nutrition 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 235000005822 corn Nutrition 0.000 description 1
• 239000013058 crude material Substances 0.000 description 1
• 238000005520 cutting process Methods 0.000 description 1
• 125000006165 cyclic alkyl group Chemical group 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• FDODVZVWGKVMBO-UHFFFAOYSA-N cyclohex-2-ene-1,4-diol Chemical compound OC1CCC(O)C=C1 FDODVZVWGKVMBO-UHFFFAOYSA-N 0.000 description 1
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
• 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• 238000013016 damping Methods 0.000 description 1
• 238000006264 debenzylation reaction Methods 0.000 description 1
• 125000006612 decyloxy group Chemical group 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 230000018044 dehydration Effects 0.000 description 1
• 238000006297 dehydration reaction Methods 0.000 description 1
• 239000008367 deionised water Substances 0.000 description 1
• 229910021641 deionized water Inorganic materials 0.000 description 1
• 210000001787 dendrite Anatomy 0.000 description 1
• 210000004268 dentin Anatomy 0.000 description 1
• 238000000586 desensitisation Methods 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• FHIVAFMUCKRCQO-UHFFFAOYSA-N diazinon Chemical compound CCOP(=S)(OCC)OC1=CC(C)=NC(C(C)C)=N1 FHIVAFMUCKRCQO-UHFFFAOYSA-N 0.000 description 1
• 125000003963 dichloro group Chemical group Cl* 0.000 description 1
• 230000000378 dietary effect Effects 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• 125000004982 dihaloalkyl group Chemical group 0.000 description 1
• 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
• QHNXEVRKFKHMRL-UHFFFAOYSA-N dimethylazanium;acetate Chemical compound CNC.CC(O)=O QHNXEVRKFKHMRL-UHFFFAOYSA-N 0.000 description 1
• ZTJBELXDHFJJEU-UHFFFAOYSA-N dimethylboron Chemical compound C[B]C ZTJBELXDHFJJEU-UHFFFAOYSA-N 0.000 description 1
• FBOFHVFMPNNIKN-UHFFFAOYSA-N dimethylquinoline Natural products C1=CC=C2N=C(C)C(C)=CC2=C1 FBOFHVFMPNNIKN-UHFFFAOYSA-N 0.000 description 1
• SNQXJPARXFUULZ-UHFFFAOYSA-N dioxolane Chemical compound C1COOC1 SNQXJPARXFUULZ-UHFFFAOYSA-N 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical group CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
• 229940043264 dodecyl sulfate Drugs 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 208000000718 duodenal ulcer Diseases 0.000 description 1
• 208000001848 dysentery Diseases 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 description 1
• 210000005069 ears Anatomy 0.000 description 1
• 230000007831 electrophysiology Effects 0.000 description 1
• 238000002001 electrophysiology Methods 0.000 description 1
• 150000002085 enols Chemical class 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
• GJTLFTOKXITQBN-UHFFFAOYSA-N ethanol hydrazine Chemical compound NN.CCO GJTLFTOKXITQBN-UHFFFAOYSA-N 0.000 description 1
• UEALHCIWELNDMN-UHFFFAOYSA-N ethyl piperidin-1-ium-1-carboxylate;chloride Chemical compound Cl.CCOC(=O)N1CCCCC1 UEALHCIWELNDMN-UHFFFAOYSA-N 0.000 description 1
• RUJPPJYDHHAEEK-UHFFFAOYSA-N ethyl piperidine-4-carboxylate Chemical compound CCOC(=O)C1CCNCC1 RUJPPJYDHHAEEK-UHFFFAOYSA-N 0.000 description 1
• 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 238000001704 evaporation Methods 0.000 description 1
• 230000008020 evaporation Effects 0.000 description 1
• 230000000763 evoking effect Effects 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 229960004979 fampridine Drugs 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 238000000855 fermentation Methods 0.000 description 1
• 230000004151 fermentation Effects 0.000 description 1
• 239000012091 fetal bovine serum Substances 0.000 description 1
• 235000019634 flavors Nutrition 0.000 description 1
• 239000011737 fluorine Substances 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 235000019253 formic acid Nutrition 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 235000011087 fumaric acid Nutrition 0.000 description 1
• 230000005714 functional activity Effects 0.000 description 1
• YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 1
• 229940074391 gallic acid Drugs 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 229960002518 gentamicin Drugs 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 239000000174 gluconic acid Chemical group 0.000 description 1
• 235000012208 gluconic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Chemical group 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 229910052737 gold Inorganic materials 0.000 description 1
• 239000010931 gold Substances 0.000 description 1
• 229960000789 guanidine hydrochloride Drugs 0.000 description 1
• PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
• 150000004820 halides Chemical class 0.000 description 1
• 150000005171 halobenzenes Chemical class 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 125000005241 heteroarylamino group Chemical group 0.000 description 1
• DCAYPVUWAIABOU-NJFSPNSNSA-N hexadecane Chemical group CCCCCCCCCCCCCCC[14CH3] DCAYPVUWAIABOU-NJFSPNSNSA-N 0.000 description 1
• OQLKNTOKMBVBKV-UHFFFAOYSA-N hexamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCCOC1=CC=C(C(N)=N)C=C1 OQLKNTOKMBVBKV-UHFFFAOYSA-N 0.000 description 1
• 229960001915 hexamidine Drugs 0.000 description 1
• PKIFBGYEEVFWTJ-UHFFFAOYSA-N hexaphene Chemical compound C1=CC=C2C=C3C4=CC5=CC6=CC=CC=C6C=C5C=C4C=CC3=CC2=C1 PKIFBGYEEVFWTJ-UHFFFAOYSA-N 0.000 description 1
• 125000004871 hexylcarbonyl group Chemical group C(CCCCC)C(=O)* 0.000 description 1
• 210000000548 hind-foot Anatomy 0.000 description 1
• 210000000003 hoof Anatomy 0.000 description 1
• 235000001050 hortel pimenta Nutrition 0.000 description 1
• 150000004677 hydrates Chemical class 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 229910000043 hydrogen iodide Inorganic materials 0.000 description 1
• 239000008309 hydrophilic cream Substances 0.000 description 1
• NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 229910052738 indium Inorganic materials 0.000 description 1
• JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 1
• LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical compound C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 1
• 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 238000003780 insertion Methods 0.000 description 1
• 230000037431 insertion Effects 0.000 description 1
• 239000013067 intermediate product Substances 0.000 description 1
• 208000028774 intestinal disease Diseases 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 125000002346 iodo group Chemical group I* 0.000 description 1
• 229910052742 iron Inorganic materials 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• LRDFRRGEGBBSRN-UHFFFAOYSA-N isobutyronitrile Chemical compound CC(C)C#N LRDFRRGEGBBSRN-UHFFFAOYSA-N 0.000 description 1
• 229960002725 isoflurane Drugs 0.000 description 1
• 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
• ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
• CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
• 230000007803 itching Effects 0.000 description 1
• 210000004731 jugular vein Anatomy 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 238000011813 knockout mouse model Methods 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 235000014655 lactic acid Nutrition 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 239000006193 liquid solution Substances 0.000 description 1
• 239000006194 liquid suspension Substances 0.000 description 1
• 239000012280 lithium aluminium hydride Substances 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 201000003265 lymphadenitis Diseases 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 229960002510 mandelic acid Drugs 0.000 description 1
• 238000004519 manufacturing process Methods 0.000 description 1
• 230000007721 medicinal effect Effects 0.000 description 1
• 229940126601 medicinal product Drugs 0.000 description 1
• 239000002609 medium Substances 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 230000006609 metabolic stress Effects 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• 229960001047 methyl salicylate Drugs 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 235000013536 miso Nutrition 0.000 description 1
• 239000011259 mixed solution Substances 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 239000002808 molecular sieve Substances 0.000 description 1
• 229910052750 molybdenum Inorganic materials 0.000 description 1
• 239000011733 molybdenum Substances 0.000 description 1
• 125000002950 monocyclic group Chemical group 0.000 description 1
• 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
• YDCVMRKHEGIECM-UHFFFAOYSA-N n,n-dimethylacetamide;1,4-dioxane Chemical compound CN(C)C(C)=O.C1COCCO1 YDCVMRKHEGIECM-UHFFFAOYSA-N 0.000 description 1
• UYZTUPSNCXHAEI-UHFFFAOYSA-N n-(9h-fluoren-1-yl)-n-phenyl-9h-fluoren-1-amine Chemical compound C=12CC3=CC=CC=C3C2=CC=CC=1N(C=1C2=C(C3=CC=CC=C3C2)C=CC=1)C1=CC=CC=C1 UYZTUPSNCXHAEI-UHFFFAOYSA-N 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• RIVIDPPYRINTTH-UHFFFAOYSA-N n-ethylpropan-2-amine Chemical compound CCNC(C)C RIVIDPPYRINTTH-UHFFFAOYSA-N 0.000 description 1
• GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
• FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
• 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
• 230000007830 nerve conduction Effects 0.000 description 1
• 230000007971 neurological deficit Effects 0.000 description 1
• 150000002828 nitro derivatives Chemical class 0.000 description 1
• 239000001272 nitrous oxide Substances 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
• 108020004707 nucleic acids Proteins 0.000 description 1
• 150000007523 nucleic acids Chemical class 0.000 description 1
• 102000039446 nucleic acids Human genes 0.000 description 1
• 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
• 210000004940 nucleus Anatomy 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-M octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 1
• LTHCSWBWNVGEFE-UHFFFAOYSA-N octanamide Chemical compound CCCCCCCC(N)=O LTHCSWBWNVGEFE-UHFFFAOYSA-N 0.000 description 1
• 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• CBFCDTFDPHXCNY-UHFFFAOYSA-N octyldodecane Natural products CCCCCCCCCCCCCCCCCCCC CBFCDTFDPHXCNY-UHFFFAOYSA-N 0.000 description 1
• 239000003883 ointment base Substances 0.000 description 1
• FATBGEAMYMYZAF-KTKRTIGZSA-N oleamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(N)=O FATBGEAMYMYZAF-KTKRTIGZSA-N 0.000 description 1
• FATBGEAMYMYZAF-UHFFFAOYSA-N oleicacidamide-heptaglycolether Natural products CCCCCCCCC=CCCCCCCCC(N)=O FATBGEAMYMYZAF-UHFFFAOYSA-N 0.000 description 1
• 238000005457 optimization Methods 0.000 description 1
• 238000003305 oral gavage Methods 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 239000012074 organic phase Substances 0.000 description 1
• 229910052762 osmium Inorganic materials 0.000 description 1
• SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 210000004681 ovum Anatomy 0.000 description 1
• WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
• 125000002971 oxazolyl group Chemical group 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• 230000008058 pain sensation Effects 0.000 description 1
• 229910003445 palladium oxide Inorganic materials 0.000 description 1
• PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
• JQPTYAILLJKUCY-UHFFFAOYSA-N palladium(ii) oxide Chemical compound [O-2].[Pd+2] JQPTYAILLJKUCY-UHFFFAOYSA-N 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Chemical group OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• 239000012188 paraffin wax Substances 0.000 description 1
• 102000045222 parkin Human genes 0.000 description 1
• 231100000915 pathological change Toxicity 0.000 description 1
• 230000036285 pathological change Effects 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• 125000005010 perfluoroalkyl group Chemical group 0.000 description 1
• 239000002304 perfume Substances 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 125000000864 peroxy group Chemical group O(O*)* 0.000 description 1
• 235000019271 petrolatum Nutrition 0.000 description 1
• 229940124531 pharmaceutical excipient Drugs 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 229960003742 phenol Drugs 0.000 description 1
• 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
• CTYRPMDGLDAWRQ-UHFFFAOYSA-N phenyl hydrogen sulfate Chemical class OS(=O)(=O)OC1=CC=CC=C1 CTYRPMDGLDAWRQ-UHFFFAOYSA-N 0.000 description 1
• 239000003016 pheromone Substances 0.000 description 1
• FVZVCSNXTFCBQU-UHFFFAOYSA-N phosphanyl Chemical group [PH2] FVZVCSNXTFCBQU-UHFFFAOYSA-N 0.000 description 1
• RYIOLWQRQXDECZ-UHFFFAOYSA-N phosphinous acid Chemical compound PO RYIOLWQRQXDECZ-UHFFFAOYSA-N 0.000 description 1
• 239000002606 phosphodiesterase VII inhibitor Substances 0.000 description 1
• 125000005496 phosphonium group Chemical group 0.000 description 1
• SXADIBFZNXBEGI-UHFFFAOYSA-N phosphoramidous acid Chemical class NP(O)O SXADIBFZNXBEGI-UHFFFAOYSA-N 0.000 description 1
• 125000002743 phosphorus functional group Chemical group 0.000 description 1
• 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 150000004885 piperazines Chemical class 0.000 description 1
• IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
• 125000003367 polycyclic group Chemical group 0.000 description 1
• 239000001103 potassium chloride Substances 0.000 description 1
• 235000011164 potassium chloride Nutrition 0.000 description 1
• 229910001414 potassium ion Inorganic materials 0.000 description 1
• 238000007781 pre-processing Methods 0.000 description 1
• 230000003518 presynaptic effect Effects 0.000 description 1
• 238000002203 pretreatment Methods 0.000 description 1
• 210000002248 primary sensory neuron Anatomy 0.000 description 1
• GGHDAUPFEBTORZ-UHFFFAOYSA-N propane-1,1-diamine Chemical compound CCC(N)N GGHDAUPFEBTORZ-UHFFFAOYSA-N 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 230000001003 psychopharmacologic effect Effects 0.000 description 1
• 210000001747 pupil Anatomy 0.000 description 1
• 150000003217 pyrazoles Chemical class 0.000 description 1
• 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
• YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical compound NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 description 1
• 150000003233 pyrroles Chemical class 0.000 description 1
• RONWGALEIBILOG-VMJVVOMYSA-N quinine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 RONWGALEIBILOG-VMJVVOMYSA-N 0.000 description 1
• 125000004548 quinolin-3-yl group Chemical group N1=CC(=CC2=CC=CC=C12)* 0.000 description 1
• XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 238000001953 recrystallisation Methods 0.000 description 1
• 239000003507 refrigerant Substances 0.000 description 1
• 230000033458 reproduction Effects 0.000 description 1
• 238000002271 resection Methods 0.000 description 1
• 235000009566 rice Nutrition 0.000 description 1
• WEMQMWWWCBYPOV-UHFFFAOYSA-N s-indacene Chemical compound C=1C2=CC=CC2=CC2=CC=CC2=1 WEMQMWWWCBYPOV-UHFFFAOYSA-N 0.000 description 1
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
• 229940081974 saccharin Drugs 0.000 description 1
• 235000019204 saccharin Nutrition 0.000 description 1
• 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
• 229960004889 salicylic acid Drugs 0.000 description 1
• KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 231100000872 sexual dysfunction Toxicity 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 239000000741 silica gel Substances 0.000 description 1
• 229910002027 silica gel Inorganic materials 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 239000002002 slurry Substances 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 239000000779 smoke Substances 0.000 description 1
• 210000002460 smooth muscle Anatomy 0.000 description 1
• URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
• WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
• 239000004299 sodium benzoate Substances 0.000 description 1
• 235000010234 sodium benzoate Nutrition 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
• 239000012312 sodium hydride Substances 0.000 description 1
• 229910000104 sodium hydride Inorganic materials 0.000 description 1
• 229910001415 sodium ion Inorganic materials 0.000 description 1
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
• MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 1
• 239000008279 sol Substances 0.000 description 1
• 239000008247 solid mixture Substances 0.000 description 1
• 238000003797 solvolysis reaction Methods 0.000 description 1
• 208000018198 spasticity Diseases 0.000 description 1
• 235000013599 spices Nutrition 0.000 description 1
• 238000013222 sprague-dawley male rat Methods 0.000 description 1
• 230000006641 stabilisation Effects 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 239000012258 stirred mixture Substances 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 230000035882 stress Effects 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 125000004646 sulfenyl group Chemical group S(*)* 0.000 description 1
• 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
• 229940124530 sulfonamide Drugs 0.000 description 1
• 150000003456 sulfonamides Chemical class 0.000 description 1
• BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
• 150000003463 sulfur Chemical class 0.000 description 1
• 125000004434 sulfur atom Chemical group 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 238000013269 sustained drug release Methods 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 210000002820 sympathetic nervous system Anatomy 0.000 description 1
• 210000000225 synapse Anatomy 0.000 description 1
• 238000001308 synthesis method Methods 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• 238000003419 tautomerization reaction Methods 0.000 description 1
• CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 1
• 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
• 150000003536 tetrazoles Chemical class 0.000 description 1
• 229910052716 thallium Inorganic materials 0.000 description 1
• BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
• CBDKQYKMCICBOF-UHFFFAOYSA-N thiazoline Chemical compound C1CN=CS1 CBDKQYKMCICBOF-UHFFFAOYSA-N 0.000 description 1
• 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
• 150000003577 thiophenes Chemical class 0.000 description 1
• 229940098465 tincture Drugs 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 150000003918 triazines Chemical class 0.000 description 1
• 206010044652 trigeminal neuralgia Diseases 0.000 description 1
• 150000003672 ureas Chemical class 0.000 description 1
• 210000003932 urinary bladder Anatomy 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 210000001835 viscera Anatomy 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 239000009891 weiqi Substances 0.000 description 1
• 239000003871 white petrolatum Substances 0.000 description 1
• 238000004804 winding Methods 0.000 description 1
• 239000002023 wood Substances 0.000 description 1
• 239000000230 xanthan gum Substances 0.000 description 1
• 229920001285 xanthan gum Polymers 0.000 description 1
• 235000010493 xanthan gum Nutrition 0.000 description 1
• 229940082509 xanthan gum Drugs 0.000 description 1